Treatment with stattic, a small-molecule alleged for STAT3 inhibition, interfered both with STAT3 and STAT1 activation, and hampered IFN-γ-induced PD-L1 expression in AML or MDS. The gene discussed is STAT1; the disease is acute myeloid leukemia.